Related Experiment Video

Updated: Jun 12, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon?

In Ah Kim1, Il Han Kim, Hak Jae Kim

  • 1Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.

Journal of Radiation Research
|May 28, 2010
PubMed

Insights

Histone deacetylase inhibitors (HDIs) enhance radiation therapy

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Histone deacetylase inhibitors (HDIs) are investigated for cancer therapy, particularly as radiosensitizers.
  • Understanding how cancer cell heterogeneity affects HDI radiosensitization is crucial for clinical application.

Purpose of the Study:

  • To evaluate the radiosensitizing effect of Trichostatin A (TSA), a HDI, across diverse human cancer cell lines.
  • To determine if p53 and ATM gene status influence TSA-mediated radiosensitization.

Main Methods:

  • In vitro radiosensitization was assessed using clonogenic assays.
  • Multiple human cancer cell lines with varying histologic origins and p53/ATM statuses were utilized.
  • Trichostatin A (TSA) was used as the HDI radiosensitizer.

Main Results:

  • TSA consistently demonstrated radiosensitization across all tested cancer cell lines.
  • The degree of radiosensitization varied among cell lines.
  • TSA-mediated radiosensitization was significantly influenced by the p53 and ATM status of the cells.

Conclusions:

  • HDIs, like TSA, can enhance radiation-induced cancer cell killing, suggesting a potential general strategy for improving radiotherapy efficacy.
  • The effectiveness of HDI radiosensitization is modulated by intrinsic cancer cell characteristics, including p53 and ATM status.
  • These findings support the potential clinical utility of HDIs in combination with radiation therapy for solid tumors.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...